Here we describe a protocol that is an adaptable, whole host, high-content screening tool that can be utilized to study host-pathogen interactions and be used for drug discovery.
A subscription to JoVE is required to view this content. Sign in or start your free trial.
Method Article
Here we describe a protocol that is an adaptable, whole host, high-content screening tool that can be utilized to study host-pathogen interactions and be used for drug discovery.
The number of new drugs identified by traditional, in vitro screens has waned, reducing the success of this approach in the search for new weapons to combat multiple drug resistance. This has led to the conclusion that researchers do not only need to find new drugs, but also need to develop new ways of finding them. Amongst the most promising candidate methods are whole-organism, in vivo assays that use high-throughput, phenotypic readouts and hosts that range from Caenorhabditis elegans to Danio rerio. These hosts have several powerful advantages, including dramatic reductions in false positive hits, as compounds that are toxic to the host and/or biounavailable are typically dropped in the initial screen, prior to costly follow up.
Here we show how our assay has been used to interrogate host variation in the well-documented C. elegans—Pseudomonas aeruginosa liquid killing pathosystem. We also demonstrate several extensions of this well-worked out technique. For example, we are able to carry out high-throughput genetic screens using RNAi in 24- or 96-well plate formats to query host factors in this host-pathogen interaction. Using this assay, whole genome screens can be completed in only a few months, which can dramatically simplify the task of identifying drug targets, potentially without the need for laborious biochemical purification approaches.
We also report here a variation of our method that substitutes the gram-positive bacterium Enterococcus faecalis for the gram-negative pathogen P. aeruginosa. Much as is the case for P. aeruginosa, killing by E. faecalis is time-dependent. Unlike previous C. elegans—E. faecalis assays, our assay for E. faecalis does not require preinfection, improving its safety profile and reducing the chances of contaminating liquid-handling equipment. The assay is highly robust, showing ~95% death rates 96 h post infection.
The identification and development of effective, broad-spectrum antibiotics, now almost a century ago, led to a watershed moment in public health where there was a wide-spread belief that infectious disease would be a scourge of the past. Within a few short decades, this optimism began to wane, as pathogen after pathogen developed resistance mechanisms that limited these once miraculous treatments. For some time, the arms race between drug discovery efforts and the pathogens seemed balanced. However, the misuse of antimicrobials has recently culminated in the emergence of pan-drug resistant strains of Klebsiella pneumoniae, Acinetobacter baumanii, Serratia marcescens, and P. aeruginosa1,2,3,4.
P. aeruginosa is an opportunistic, gram negative, multi-host pathogen that is a severe threat to patients with severe burns, those who are immunocompromised, or have cystic fibrosis. It is also increasingly identified as a causative agent in severe nosocomial infections, particularly due to its ongoing acquisition of antimicrobial resistance. To begin to address this threat, we have used the well-documented C. elegans-P. aeruginosa infection system5. Our lab has leveraged this system to develop a liquid-based, high-throughput, high-content screening platform to identify novel compounds that limit the ability of the pathogen to kill the host6. Intriguingly, these compounds seem to belong to at least three general categories, including antimicrobials7 and virulence inhibitors8. Other high-content drug discovery assays in C. elegans have been reported for Mycobacterium tuberculosum, Chlamydia trachomatis, Yersinia pestis, Listeria monocytogenes, Francisella tularensis, Staphylococcus aureus, Candida albicans, and Enterococcus faecalis, among others9,10,11,12,13,14,15,16. These types of assays have several well-recognized advantages, such as limiting false positive hits that may be toxic to both the host and the pathogen, increased likelihood of bioavailability compared to a chemical screen, and the ability to identify hits beyond simply limiting microbial growth, such as anti-virulents, immune stimulatory molecules, or compounds that otherwise tilt the balance of the host-pathogen interaction in favor of the former. Additionally, the compounds discovered in these screens are often effective in mammalian hosts.
It is worth noting that at least two other assays17,18 are available to carry out high-throughput screens in C. elegans in liquid. However, each of these assays is a modification that allows the prototypical intestinal-colonization assay, known as slow-killing, to be performed in liquid, increasing throughput and allowing compounds to be more readily screened. Careful characterization has conclusively demonstrated that the mechanisms of bacterial virulence are different between these assays and our liquid-based screen7. Since both types of virulence are observed in mammalian systems, it is important to consider which virulence determinant is most relevant for the experimenter's interests prior to assay selection.
Here we demonstrate an optimized version of the liquid-based C. elegans-P. aeruginosa assay. We also report the adaptation of our liquid-based assay method to accommodate the gram-positive bacterial pathogen Enterococcus faecalis. Like P. aeruginosa, E. faecalis is increasingly identified as a serious nosocomial threat with a growing armament of antimicrobial resistance pathways1. Although a previous method for high-throughput screening of E. faecalis exists14, it requires preinfection with the pathogen, which complicates the procedure and increases the likelihood of contaminating equipment like the COPAS FlowSort. Our protocol eliminates the need for pre-infection, improving the safety profile. Finally, we report a means by which either of these assays can be combined with feeding RNAi, allowing the user to search for host factors that play a role in the establishment of, or resistance to, infection.
Access restricted. Please log in or start a trial to view this content.
Caution: P. aeruginosa and E. faecalis are Biosafety Level 2 pathogens, and proper safety precautions must be taken to prevent accidental infection and to minimize contamination of surfaces. All media and materials that come into contact with pathogens must be sterilized and/or discarded. Further guidelines are available from the CDC publication Biosafety in Microbiological and Biomedical Laboratories (BMBL), 5th edition.
1. Preparation and Maintenance of P. aeruginosa
2. Preparation of RNAi Bacteria
3. Maintenance and Preparation of C. elegans
Note: Before initiating experiments, generate a synchronized population of gravid, adult hermaphroditic worms as follows.
4. Liquid Killing Assay Setup (Basic Protocol)
Note: This is a protocol for one bacterial strain and one source of worms.
5. Adaptation for Screening Multiple C. elegans Strains or Knockdowns (RNAi Screen Setup)
Note: This is an RNAi screen described for a 24-well plate setup.
6. Adaptation for E. faecalis
Note: Only the differences from P. aeruginosa assay are described.
Access restricted. Please log in or start a trial to view this content.
Important parameters for assay performance
A proper understanding of the biology underlying this assay is necessary for troubleshooting and optimizing the assay. To that end, we refer first to several key papers elucidating the mechanisms of pathogenesis of P. aeruginosa-mediated killing in liquid7,20. Provided that the steps outlined above are followed...
Access restricted. Please log in or start a trial to view this content.
This assay (or similar assays where other pathogens are substituted for P. aeruginosa or E. faecalis) is useful for a variety of purposes, including drug discovery. It is also useful for addressing fundamental biological questions, such as identifying virulence factors, the elucidation of host defense pathways, and determining the regulatory machinery involved in the host-pathogen interaction.
Although the P. aeruginosa Liquid Killing assay is robust, there are sever...
Access restricted. Please log in or start a trial to view this content.
The authors declare that they have no conflicts of interest to disclose.
This study was supported by the Cancer Prevention and Research Institute of Texas (CPRIT) Award RR150044, Welch Foundation Research Grant C-1930, and by the National Institutes of Health K22 AI110552 awarded to NVK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Access restricted. Please log in or start a trial to view this content.
| Name | Company | Catalog Number | Comments |
|---|---|---|---|
| COPAS FP BioSorter | Union Biometrica | Large object flow cytometer/worm sorter | |
| Cytation 5 | BioTek | ||
| EL406 Washer Dispenser | BioTek | ||
| Multitron Pro | Infors HT | ||
| 24 Deep-Well RB Block | Thermo Fisher Scientific | CS15124 | |
| 384-Well plate | Greiner Bio-One | MPG-781091 | |
| Nematode Growth Media (NGM) | Amount per liter: 18 grams agar, 3 grams NaCl, 2.5 grams Peptone, 1 mL CaCl2 (1 M), 1 mL MgSO4 (1 M), 25 mL Phospate buffer, and 973 mL of milli-Q water | ||
| Slow Killing (SK) plates | Amount per liter: 18 grams agar, 3 grams NaCl, 3.5 grams Peptone, 1 mL CaCl2 (1 M), 1 mL MgSO4 (1 M), 25 mL Phospate buffer, and 973 mL of milli-Q water | ||
| Slow Killing (SK) media | Amount per liter: 3 grams NaCl, 3.5 grams Peptone, 1 mL CaCl2 (1 M), 1 mL MgSO4 (1 M), 25 mL Phosphate buffer, and 973 mL of milli-Q water | ||
| Lysogeny Broth (LB) | USBiological Life Sciences | L1520 | |
| Brian Heart Infusion broth (BHI) | Research Products International Corp | 50-488-526 | |
| Worm Bleach Solution | Amount per 100 mL: 10 mL of 5 M NaOH solution, 20 mL of 5% Sodium Hypochlorite Solution, and 70 mL of sterile water | ||
| S Basal | Amount per liter: 5.85 grams NaCl, 6 grams KH2PO4, 1 gram K2HPO4, and 1 Liter of milli-Q water | ||
| Agar | USBiological Life Sciences | A0930 | |
| NaCl | USBiological Life Sciences | S5000 | |
| Peptone | USBiological Life Sciences | P3300 | |
| CaCl2 | USBiological Life Sciences | ||
| MgSO4 | Fisher Scientific | M63-500 | |
| Phospate buffer | amount per liter: 132 mL of K2HPO4 (1M) and 868 mL of KH2PO4 (1M) | ||
| KH2PO4 | Acros Organics | 7778-77-0 | |
| K2HPO4 | USBiological Life Sciences | P5100 | |
| 5% Sodium Hypochlorite Solution | BICCA | 7495.5-32 | |
| NaOH solution | Fisher Scientific | SS255-1 | |
| Breathe-easy | Diversified Biotech | BEM-1 | |
| SYTOX Orange Nucleic Acid Stain | Fisher Scientific | S11368 | |
| Bacterial Strains | |||
| P. aeruginosa (PA14) | |||
| E. faecalis(OG1RF) | |||
| E. coli superfood (OP50) | |||
| E. coli RNAi expressing bacteria (HT115) | |||
| Worm Strains | |||
| glp-4(bn2) (Beanan and Strome, 1992, PMID: 1289064) | |||
| PINK-1::GFP reporter (Kang et al., 2018, PMID: 29532717) |
Access restricted. Please log in or start a trial to view this content.